{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:49:13Z","timestamp":1776872953971,"version":"3.51.2"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>With a large proportion of the US adult population vaccinated against SARS-CoV-2, it is important to identify who remains at risk of severe infection despite vaccination.<\/jats:p><\/jats:sec>Objective<\/jats:title>To characterize risk factors for severe COVID-19 disease in a vaccinated population.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This nationwide, retrospective cohort study included US veterans who received a SARS-CoV-2 vaccination series and later developed laboratory-confirmed SARS-CoV-2 infection and were treated at US Department of Veterans Affairs (VA) hospitals. Data were collected from December 15, 2020, through February 28, 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Demographic characteristics, comorbidities, immunocompromised status, and vaccination-related variables.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Development of severe vs nonsevere SARS-CoV-2 infection. Severe disease was defined as hospitalization within 14 days of a positive SARS-CoV-2 diagnostic test and either blood oxygen level of less than 94%, receipt of supplemental oxygen or dexamethasone, mechanical ventilation, or death within 28 days. Association between severe disease and exposures was estimated using logistic regression models.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 110\u202f760 patients with infections following vaccination (97\u202f614 [88.1%] men, mean [SD] age at vaccination, 60.8 [15.3] years; 26\u202f953 [24.3%] Black, 11\u202f259 [10.2%] Hispanic, and 71\u202f665 [64.7%] White), 10\u202f612 (9.6%) had severe COVID-19. The strongest association with risk of severe disease after vaccination was age, which increased among patients aged 50 years or older with an adjusted odds ratio (aOR) of 1.42 (CI, 1.40-1.44) per 5-year increase in age, such that patients aged 80 years or older had an aOR of 16.58 (CI, 13.49-20.37) relative to patients aged 45 to 50 years. Immunocompromising conditions, including receipt of different classes of immunosuppressive medications (eg, leukocyte inhibitor: aOR, 2.80; 95% CI, 2.39-3.28) or cytotoxic chemotherapy (aOR, 2.71; CI, 2.27-3.24) prior to breakthrough infection, or leukemias or lymphomas (aOR, 1.87; CI, 1.61-2.17) and chronic conditions associated with end-organ disease, such as heart failure (aOR, 1.74; CI, 1.61-1.88), dementia (aOR, 2.01; CI, 1.83-2.20), and chronic kidney disease (aOR, 1.59; CI, 1.49-1.69), were also associated with increased risk. Receipt of an additional (ie, booster) dose of vaccine was associated with reduced odds of severe disease (aOR, 0.50; CI, 0.44-0.57).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this nationwide, retrospective cohort of predominantly male US Veterans, we identified risk factors associated with severe disease despite vaccination. Findings could be used to inform outreach efforts for booster vaccinations and to inform clinical decision-making about patients most likely to benefit from preexposure prophylaxis and antiviral therapy.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.40037","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T15:03:42Z","timestamp":1666278222000},"page":"e2240037","source":"Crossref","is-referenced-by-count":57,"title":["Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals"],"prefix":"10.1001","volume":"5","author":[{"given":"Austin D.","family":"Vo","sequence":"first","affiliation":[{"name":"VA Boston Cooperative Studies Program, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"La","sequence":"additional","affiliation":[{"name":"VA Boston Cooperative Studies Program, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie T.-Y.","family":"Wu","sequence":"additional","affiliation":[{"name":"VA Palo Alto Healthcare System, Palo Alto, California"},{"name":"Stanford University School of Medicine, Stanford, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith M.","family":"Strymish","sequence":"additional","affiliation":[{"name":"Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Ronan","sequence":"additional","affiliation":[{"name":"Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Brophy","sequence":"additional","affiliation":[{"name":"VA Boston Cooperative Studies Program, Boston, Massachusetts"},{"name":"Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts"},{"name":"Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nhan V.","family":"Do","sequence":"additional","affiliation":[{"name":"VA Boston Cooperative Studies Program, Boston, Massachusetts"},{"name":"Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts"},{"name":"Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Westyn","family":"Branch-Elliman","sequence":"additional","affiliation":[{"name":"VA Boston Cooperative Studies Program, Boston, Massachusetts"},{"name":"Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"VA Boston Center for Healthcare Organization and Implementation Research, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathanael R.","family":"Fillmore","sequence":"additional","affiliation":[{"name":"VA Boston Cooperative Studies Program, Boston, Massachusetts"},{"name":"Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Monach","sequence":"additional","affiliation":[{"name":"VA Boston Cooperative Studies Program, Boston, Massachusetts"},{"name":"Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"issue":"4","key":"zoi221134r1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/s41591-022-01699-1","article-title":"Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England.","volume":"28","author":"Andrews","year":"2022","journal-title":"Nat Med"},{"issue":"15","key":"zoi221134r2","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against COVID-19 in Israel.","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"issue":"10328","key":"zoi221134r3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"zoi221134r5","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2022.13","article-title":"The COVID-19 hospitalization metric in the pre- and post-vaccination eras as a measure of pandemic severity: a retrospective, nationwide cohort study.","author":"Fillmore","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"key":"zoi221134r6","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2022.79","article-title":"Coronavirus disease 2019 (COVID-19) hospitalization metrics that do not account for disease severity underestimate protection provided by severe acute respiratory coronavirus virus 2 (SARS-CoV-2) vaccination and boosting: a retrospective cohort study.","author":"Corrigan","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"zoi221134r9","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1080\/03610911003650383","article-title":"How big is a big odds ratio? interpreting the magnitudes of odds ratios in epidemiological studies.","volume":"39","author":"Chen","year":"2010","journal-title":"Commun Stat Simul Comput"},{"issue":"9","key":"zoi221134r11","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2204919","article-title":"Nirmatrelvir use and severe COVID-19 outcomes during the Omicron surge.","volume":"387","author":"Arbel","year":"2022","journal-title":"N Engl J Med"},{"key":"zoi221134r12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","article-title":"Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.","volume":"94","author":"Yang","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"15","key":"zoi221134r13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","article-title":"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019\u2014COVID-NET, 14 States, March 1\u201330, 2020.","volume":"69","author":"Garg","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"13","key":"zoi221134r14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.15585\/mmwr.mm6913e2","article-title":"Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019\u2014United States, February 12\u2013March 28, 2020.","volume":"69","author":"CDC COVID-19 Response Team","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"24","key":"zoi221134r15","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1182\/blood.2019000406","article-title":"With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study.","volume":"133","author":"Fillmore","year":"2019","journal-title":"Blood"},{"issue":"15","key":"zoi221134r17","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1056\/NEJMe2113151","article-title":"COVID-19 vaccine effectiveness and the test-negative design.","volume":"385","author":"Dean","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi221134r18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.15585\/mmwr.mm7101a4","article-title":"Risk factors for severe COVID-19 outcomes among persons aged =18 years who completed a primary COVID-19 vaccination series\u2014465 health care facilities, United States, December 2020-October 2021.","volume":"71","author":"Yek","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"zoi221134r19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cmi.2021.09.036","article-title":"Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.","volume":"28","author":"Galmiche","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"zoi221134r20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1001\/jamainternmed.2021.7024","article-title":"Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US.","volume":"182","author":"Sun","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"24","key":"zoi221134r21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel.","volume":"385","author":"Goldberg","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi221134r22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by COVID-19 vaccines.","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi221134r23","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/apt.v55.10","article-title":"Effectiveness and safety of SARS-CoV-2 vaccine in inflammatory bowel disease patients: a systematic review, meta-analysis and meta-regression.","volume":"55","author":"Bhurwal","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"zoi221134r4","author":"US Department of Veterans Affairs"},{"key":"zoi221134r7","unstructured":"Centers for Medicare & Medicaid Services. Chronic Conditions Data Warehouse. Accessed November 30, 2021. https:\/\/www2.ccwdata.org\/web\/guest\/condition-categories"},{"key":"zoi221134r8","unstructured":"University of Toronto Department of Statistics. Odds ratios and relative risk. Accessed July 25, 2022. https:\/\/www.utstat.utoronto.ca\/reid\/odds.pdf"},{"key":"zoi221134r10","unstructured":"Monach? P, Branch-Elliman? W. From pandemic to endemic. Contagion. 2022;7(1). Accessed September 20, 2022. https:\/\/www.contagionlive.com\/view\/from-pandemic-to-endemic"},{"key":"zoi221134r16","unstructured":"US Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Accessed June 1, 2022. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/covid-data\/covid-net\/purpose-methods.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2797495\/vo_2022_oi_221134_1675696849.05149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T16:02:44Z","timestamp":1676304164000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.40037","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]}}}